Physician profile
Paul E Williams
NPI 1487682613
$1,292.67
in general payments reported to CMS, 2019-2025
11 companies · $239 in 2025
The $239 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $420 · 2020: $162 · 2021: $258 · 2022: $78.61 · 2023: $34.70 · 2024: $100 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $373.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $381.99 | 2019-2025 | Exalt Model D |
| Abbvie INC. | $270.50 | 2021-2024 | Linzess, Viberzi |
| Shire North American Group INC | $200.00 | 2019 | |
| Medtronic, INC. | $143.63 | 2025 | Manoscan |
| Janssen Biotech, INC. | $110.19 | 2019-2024 | Tremfya |
| Olympus America INC. | $71.17 | 2020 | |
| Pfizer INC. | $35.72 | 2021 | |
| Endogastric Solutions, INC | $24.92 | 2024 | Esophyx |
| Astrazeneca Pharmaceuticals Lp | $21.52 | 2022 | |
| Nestle Healthcare Nutrition INC. | $18.76 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.